CD8A and neoplasm: Ipilimumab, a CTLA-4 inhibitor, lowers the T cell activation threshold and expands melanoma-reactive CD8+ T cell populations (29), while selectively depleting tumor-infiltrating Tregs via antibody-dependent cellular cytotoxicity (ADCC) (30).